Find a Clinical Trial

Showing 151 - 160 of 235 Trials

A Phase 1b/2 Pressure Enabled Regional Immuno-Oncology Study of Hepatic Arterial Infusion of SD-101 with Systemic Checkpoint Blockade for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT05220722

Population:

Adult

Phase:

I/II

The purpose of this study is to determine the safety and best dose of SD-101 given by hepatic artery infusion (HAI, a method of putting medication directly into your liver) using Pressure- Enabled Drug Delivery (PEDD) alone or in combination with either pembrolizumab or in combination with nivolumab and ipilimumab. SD-101 works by limiting the expression, or present of, TLR9 in your body, which when present in large amounts, helps your tumor to grow. The study also aims to find out what effects (both good and bad) SD-101 given by HAI with PEDD has on you and your cancer when given alone or...
A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular Carcinoma (Morpheus-Neo-HCC)

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT05908786

Population:

Adult

Phase:

I/II

The purpose of this study is to compare the effects, good or bad, of the cancer immunotherapy (CIT) combinations on you and your liver cancer, to find out which is better when given prior to surgery to remove your cancer. The study drugs are Atezolizumab, Bevacizumab, Tiragolumab, and RO7247669.The CIT combinations are experimental drug treatments, which means health authorities have not approved them for the treatment of liver cancer in the neoadjuvant for treating cancer before surgery. Are you Eligible? (Inclusion Criteria) • Signed Informed Consent Form • Age ≥ 18 years at...
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With

Principal Investigator:

Yoanna S Pumpalova, MD

Contact Number:

212-342-5162

NCT Number:

NCT05609370

Population:

Adult

Phase:

I/II

The purpose of this study is safety, tolerability and efficacy of a combined treatment of LBL-007 and tislelizumab in combination with bevacizumab and capecitabine. LBL-007 and tislelizumab has not yet been approved by the Food and Drug Administration (FDA). Bevacizumab and capecitabine are approved for use in colorectal cancer, but their use in combination with LBL- 007 alone or LBL-007 in combination with tislelizumab is not. Tislelizumab affects cells in your immune system, making them more likely to attack cancer cells. Tislelizumab does this by binding to a part of your immune cells...
A Phase 1/2 Study of ONCT-534 in Subjects with Metastatic Castration-Resistant Prostate Cancer

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT05917470

Population:

Adult

Phase:

I/II

The main purpose of this study is to see if ONCT-534 is safe and useful for treating people with R/R mCRPC, when other treatments are not working. ONCT-534 has not been approved by the Food and Drug Administration (FDA). This is a first in human study. We will ask you to have blood drawn, biopsy, physical exam, and tumor imaging such as CT scan, MRI, and bone scan. You may be in this study up to 2 years. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - No history of seizure disorder(s) - No major surgery within 30 days prior to start of study drug
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT02332668

Population:

Pediatrics

Phase:

I/II

This is a two-part study of pembrolizumab (MK-3475) in pediatric participants who have either advanced melanoma, relapsed or refractory classical Hodgkin lymphoma (rrcHL) or advanced, relapsed or refractory programmed cell death ligand 1 (PD-L1) positive malignant solid tumor or other lymphoma. Part 1 will find the maximum tolerated dose (MTD)/maximum administered dose (MAD), confirm the dose, and find the recommended Phase 2 dose (RP2D) for pembrolizumab therapy. Part 2 will further evaluate the safety and efficacy at the pediatric RP2D. This study is being sponsored by the Children's...
A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, andEfficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null SolidTumors

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT05975073

Population:

Adult

Phase:

I/II

The purpose of this study is to assess how the study drugs, AMG 193 and IDE397, move throughout the body, how the study drugs work in the body, whether they are safe, and an effective treatment option for people with advanced solid tumors lacking methylthioadeosine phosphorylase (MTAP) in the DNA (genetic material). Lacking MTAP may limit the way in which the enzyme, protein arginine methyltransferase 5 (PRMT5) works. PRMT5 is important for cancer cell survival and works with an enzyme methionine adenosyltransferase 2A (MAT2A). AMG193 may further slow down PRMT5 activity and kill cancer cells...
A Phase I/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti tumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors

Principal Investigator:

Brian Henick, MD

Contact Number:

212-342-5162

NCT Number:

NCT05914116

Population:

Adult

Phase:

I/II

DB-1311 (study drug) is an investigational antibody-drug conjugate (antibody that guides the study drug to cancer cells) composed of an anti-B7-H3 (a protein associated with worse overall survival and drug resistance) antibody and P1021 (slows DNA replication in cancer cells). Investigational means the study drug being tested is not approved by the United States (U.S.) Food and Drug Administration (FDA). The main goal of this study is to test whether the study drug is safe and tolerable in patients with certain types of cancer. This study will also measure the amount of the study drug in...
LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Patients with an Advanced Solid Tumor

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT04939610

Population:

Adult

Phase:

I/II

The purpose of this study is to test the safety of the experimental drugs called 68Ga-FAP-2286 and 177Lu-FAP-2286. 8Ga-FAP-2286 is an imaging agent that targets a certain protein which has been found in certain tumors called Fibroblast activation protein (FAP). Imaging using 68Ga-FAP-2286 will determine if participants are eligible to receive the experimental radiotherapy, 177Lu-FAP-2286, which researchers think may kill cancer cells by delivering radiation to cancer cells that have fibroblast activation protein (FAP). Are you Eligible? (Inclusion Criteria) Have you been diagnosed with...
MORAb-202-G000-201: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types

Principal Investigator:

June Y. Hou, MD

Contact Number:

212-342-5162

NCT Number:

NCT04300556

Population:

Adult

Phase:

I/II

The purpose of the first part of this study, the Dose Escalation part, is to study and identify the highest tolerable safe dose of MORAb-202. The purpose of the Expansion part is to further investigate how the different tumor types being studied respond to the study drug and to gather more information on its safety and effectiveness. This study will enroll patients with triple-negative breast cancer (TNBC), endometrial cancer (EC), non-small cell lung cancer (NSCLC, adenocarcinoma), and ovarian cancer. If it is determined that you meet all of the study entry requirements, you will get an...
PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-Unresponsive, BCG-RelaPsing, and High-Risk BCG-Naive Non-muscle Invasive UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243

Principal Investigator:

Christopher B Anderson, MD

Contact Number:

212-342-5162

NCT Number:

NCT03317158

Population:

Adult

Phase:

I/II

This study is for patients who have bladder cancer that has not invaded muscle tissue and who have been treated with one or more surgical resections and Bacillus Calmette-Guerin or BCG, which was directly given into the bladder before. The main purpose of this trial is to show that durvalumab is safe when given alone, in combination with BCG treatments, and in combination with radiation therapy for patients whose bladder cancer has now come back. The overall goal of this trial is to see if the risk of the bladder cancer coming back can be decreased with this treatment regimen. Are you...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages